What is Ascletis Pharma Inc.'s contact information?

Ascletis Pharma Inc.'s contact information: hr@ascletis.com, pr@ascletis.com, bd@ascletis.com, clinicaltrials@ascletis.com, +8657185389729.

How many employees does Ascletis Pharma Inc. have?

Ascletis Pharma Inc. has 37 employees.

What industry does Ascletis Pharma Inc. belong to?

Ascletis Pharma Inc. is in the industry of: Pharmaceuticals, Biotechnology, Healthcare, Pharmaceutical Manufacturing.

What are Ascletis Pharma Inc.'s official social media profiles?

Ascletis Pharma Inc. Linkedin Page

What tech stack does Ascletis Pharma Inc. use?

Some of the popular technologies that Ascletis Pharma Inc. uses are: CNZZ, Baidu Analytics, GoDaddy, jQuery.

What are Ascletis Pharma Inc.'s office addresses?

Ascletis Pharma Inc. has a known office at the following address: 浙江省杭州市萧山区杭州湾信息港D栋12楼杭州市, 浙江省 311200, CN.

What is Ascletis Pharma Inc.'s estimated annual revenue?

Ascletis Pharma Inc.'s revenue is $9,539,000

What is Ascletis Pharma Inc.'s open headcount?

Ascletis Pharma Inc. has no job postings yet.

What is the number of ad campaigns for Ascletis Pharma Inc.?

Ascletis Pharma Inc. has no advertisements yet.

What is the number of recent news articles about Ascletis Pharma Inc.?

Ascletis Pharma Inc. has 94 news articles.

Ascletis Pharma Inc. - Pubrio Company Profile & Intent

Ascletis Pharma Inc.

China · Pharmaceutical Manufacturing

Pharmaceuticals

Biotechnology

Healthcare

Pharmaceutical Manufacturing

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.